Cargando…

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy

Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barca, Cristina, Griessinger, Christoph M., Faust, Andreas, Depke, Dominic, Essler, Markus, Windhorst, Albert D., Devoogdt, Nick, Brindle, Kevin M., Schäfers, Michael, Zinnhardt, Bastian, Jacobs, Andreas H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780589/ https://www.ncbi.nlm.nih.gov/pubmed/35056071 http://dx.doi.org/10.3390/ph15010013

Ejemplares similares

In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation
por: Zinnhardt, Bastian, et al.
Publicado: (2018)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI
por: Foray, Claudia, et al.
Publicado: (2022)

The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)
por: Barca, Cristina, et al.
Publicado: (2021)

Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals
por: Carter, Korey P., et al.
Publicado: (2020)

A Longitudinal PET/MRI Study of Colony-Stimulating Factor 1 Receptor–Mediated Microglia Depletion in Experimental Stroke
por: Barca, Cristina, et al.
Publicado: (2022)

Short-Term Colony-Stimulating Factor 1 Receptor Inhibition–Induced Repopulation After Stroke Assessed by Longitudinal (18)F-DPA-714 PET Imaging
por: Barca, Cristina, et al.
Publicado: (2022)

Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology
por: Rahmim, Arman, et al.
Publicado: (2022)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

It is time to move forward into the era of Theranostics
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2018)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
por: Funeh, Cyprine Neba, et al.
Publicado: (2023)

In Vivo Quantitative Imaging of Glioma Heterogeneity Employing Positron Emission Tomography
por: Barca, Cristina, et al.
Publicado: (2022)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Towards Optimized Bioavailability of (99m)Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity
por: Honold, Lisa, et al.
Publicado: (2021)

Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents
por: Nurhidayah, Wiwit, et al.
Publicado: (2022)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Position statement on radiopharmaceutical production for clinical trials
por: Bormans, G., et al.
Publicado: (2017)

Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma
por: Foster, Alexandra, et al.
Publicado: (2021)

Theranostics in nuclear medicine practice
por: Yordanova, Anna, et al.
Publicado: (2017)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Molecular Imaging of Immune Cell Dynamics During De- and Remyelination in the Cuprizone Model of Multiple Sclerosis by [(18)F]DPA-714 PET and MRI
por: Zinnhardt, Bastian, et al.
Publicado: (2019)

Imaging temozolomide-induced changes in the myeloid glioma microenvironment
por: Foray, Claudia, et al.
Publicado: (2021)

Multimodal imaging reveals temporal and spatial microglia and matrix metalloproteinase activity after experimental stroke
por: Zinnhardt, Bastian, et al.
Publicado: (2015)

Impact of hydroxytyrosol on stroke: tracking therapy response on neuroinflammation and cerebrovascular parameters using PET-MR imaging and on functional outcomes
por: Barca, Cristina, et al.
Publicado: (2021)

Theranostic Role of (32)P-ATP as Radiopharmaceutical for the Induction of Massive Cell Death within Avascular Tumor Core
por: Galiè, Mirco, et al.
Publicado: (2017)

Preparation, Characterization, and Preliminary Imaging Study of [(188)Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis
por: Xu, Tingting, et al.
Publicado: (2022)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

Dose-Dependent Internalization and Externalization Integrity Study of Newly Synthesized (99m)Tc-Thymoquinone Radiopharmaceutical as Cancer Theranostic Agent
por: Tariq, Saima, et al.
Publicado: (2020)

Initial experience with [(18)F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system
por: Backhaus, Philipp, et al.
Publicado: (2020)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Multimodal Imaging of Patients With Gliomas Confirms (11)C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy
por: Laukamp, Kai R., et al.
Publicado: (2017)

Production and separation of (43)Sc for radiopharmaceutical purposes
por: Domnanich, Katharina A., et al.
Publicado: (2017)

Radiopharmaceuticals in monitoring cancer
por: Britton, Keith E., et al.
Publicado: (2015)

Are we “preparing” radiopharmaceuticals?
por: Decristoforo, Clemens, et al.
Publicado: (2016)

MIB Guides: Preclinical radiopharmaceutical dosimetry
por: Carter, Lukas M., et al.
Publicado: (2023)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Transport processes of radiopharmaceuticals and -modulators
por: Efferth, Thomas, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_odst9lu8fdg61sfvs9uvnht9v4